Abstract
The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective in the treatment of chronic heart failure due to LV systolic dysfunction.
Mesoblast Investigational Site 10757 – Cardiology, P.C., Birmingham, Alabama, United States
Mesoblast Investigational Site 13262 – University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
Mesoblast Investigational Site 10779 – Mercy Gilbert Medical Center, Gilbert, Arizona, United States
(and 56 more...)
ClinicalTrials.gov Identifier: NCT02032004.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Weiss, J.N. (2022). Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. In: Stem Cell Surgery Trials in Heart Failure and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-78010-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-78010-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-78009-8
Online ISBN: 978-3-030-78010-4
eBook Packages: MedicineMedicine (R0)